P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL

• Jesse Tettero,
• Raffaele Palmieri,
• Lok Lam Ngai,
• Costa Bachas,
• Valentina Arena,
• Dimitri Breems,
• Thomas Fischer,
• Bjorn Tore Gjertsen,
• Laimonas Griškevičius,
• Gunnar Juliusson,
• Johan Maertens,
• Markus Manz,
• Luca Maurillo,
• Thomas Pabst,
• Jakob Passweg,
• Alfonso Piciocchi,
• Kimmo Porkka,
• Bob Löwenberg,
• Adriano Venditti,
• Gert Ossenkoppele,
• Francesco Buccisano,
• Jacqueline Cloos

Affiliations

Jesse Tettero

1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Raffaele Palmieri

2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy

Lok Lam Ngai

1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Costa Bachas

1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Valentina Arena

3 GIMEMA Data Center, Rome, Italy

Dimitri Breems

4 Ziekenhuis Netwerk Antwerpen, Department of Hematology, Antwerpen, Belgium

Thomas Fischer

5 Otto-von-Guericke-University Magdeburg, Department of Hematology and Oncology, Magdeburg, Germany

Bjorn Tore Gjertsen

6 Haukeland University Hospital, Department of Medicine, Hematology Section, Bergen, Norway

Laimonas Griškevičius

7 Vilnius University Hospital Santaros Klinikos and Vilnius University, Hematology, Oncology, Transfusion Medicine Center, Vilnius, Lithuania

Gunnar Juliusson

8 Skanes University Hospital, Department of Hematology, Lund, Sweden

Johan Maertens

9 University Hospital Gasthuisberg, Department of Hematology, Leuven, Belgium

Markus Manz

10 University Hospital of Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland

Luca Maurillo

2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy

Thomas Pabst

11 Inselspital, University Hospital, Department of Medical Oncology, Bern, Switzerland

Jakob Passweg

12 University Hospital, Basel, Department of Hematology, Basel, Switzerland

Alfonso Piciocchi

3 GIMEMA Data Center, Rome, Italy

Kimmo Porkka

13 Helsinki University Hospital Cancer Center, Department of Hematology, Helsinki, Finland

Bob Löwenberg

14 Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Adriano Venditti

2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy

Gert Ossenkoppele

1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Francesco Buccisano

2 University of Rome “Tor Vergata”, Department of Biomedicine and Prevention, Rome, Italy

Jacqueline Cloos

1 Amsterdam UMC, location Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands